刍议舒洛地特联合活性维生素D_3治疗IgA肾病的临床疗效  

Analysis of Clinical Curative Effect of Sulodexide Combined with Active Vitamine D_3 in Treatment of IgA Nephropathy

作　　者：孙婷丽[1] 杨静波[1] 董文鹏[2] 孙薇[1] 刘继章[1] SUN Ting-li;YANG Jing-bo;DONG Wen-peng;SUN Wei;LIU Ji-zhang(Department of Nephrology,General Hospital of Daqing Oil Field,Daqing,Heilongjiang Province,163001 China;Hemodialysis Room,General Hospital of Daqing Oil Field,Daqing,Heilongjiang Province,163001 China)

机构地区：[1]大庆油田总医院肾内科,黑龙江大庆163001 [2]大庆油田总医院血液透析室,黑龙江大庆163001

出　　处：《中外医疗》2018年第11期122-123,126,共3页China & Foreign Medical Treatment

摘　　要：目的观察舒洛地特联合活性维生素D3治疗IgA肾病的临床疗效。方法将2014年12月—2017年12月期间于该院收治的IgA肾病患者中随机抽选出40例作为该研究的分析对象,将其平均分成观察组(20例)与对照组(20例)后,分别给予患者使用替米沙坦、舒洛地特联合活性维生素D3和替米沙坦进行临床治疗。比较两组患者治疗前后肾功能、24 h尿蛋白定量及不良反应发生率,并判断其临床治疗效率。结果治疗后,观察组治疗后的24 h尿蛋白定量为(1.05±0.40)g,较对照组低(t=4.52,P<0.05);观察组治疗后的PT、FIB、APTT及TT等凝血功能指标分别为(12.72±1.78)s、(2.52±0.49)g/L、(23.11±5.14)s、(17.88±0.63)s均较对照组对应值稳定(t=3.26、3.66、3.11、4.52,P<0.05);观察组无不良反应,对照组有4例不良反应(χ2=4.44,P<0.05)。结论在患者服用替米沙坦的同时使用静脉滴注舒洛地特及服用活性维生素D3能降低患者蛋白尿,有效增强IgA肾病疗效的同时有助于维持其凝血指标的稳定性,具有临床推广价值。Objective To observe the clinical curative effect of sulodexide combined with active vitamine D3 in treatment of IgA nephropathy. Methods 40 cases of patients with IgA nephropathy admitted and treated in our hospital from December2014 to December 2017 were selected and randomly divided into two groups with 20 cases in each, respectively treated with telmisartan, sulodexide combined with active vitamine D3 and telmisartan, and the renal function, quantitative of ptoteinuria in 24 hour and incidence rate of adverse reactions were compared between the two groups, and the clinical treatment effective rate was determined. Results After treatment, the quantitative of ptoteinuria in 24 hour in the observation group was lower than that in the control group（t=4.52,P〈0.05）, which was（1.05±0.40）g in the observation group, and the PT,FIB,APTT,TT in the observation group after treatment were steadier than those in the control group, which were respectively（12.72 ±1.78）s,（2.52±0.49）g/L,（23.11±5.14）s,（17.88±0.63）s in the observation group（t=3.26,3.66,3.11,4.52,P〈0.05）, and there were no adverse reactions in the observation group, and there were 4 cases with adverse reactions in the control group（χ2=4.44,P〈0.05）. Conclusion The telmisartan and intravenous drip of sulodexide combined with active vitamine D3 can reduce the proteinuria, and effectively enhancing the curative effect of IgA nephropathy contributes to maintaining the stability of coagulation indexes, with clinical promotion value.

关 键 词：IGA肾病 舒洛地特 活性维生素D3 

分 类 号：R692[医药卫生—泌尿科学]